Method for modifying, diagnosing, and screening for IGF-I sensit

Details Method for modifying, diagnosing, and screening for IGF-I sensit Method for modifying, diagnosing, and screening for IGF-I sensit

1994-07-25

1997-11-11

Ulm, John

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530303, A61K 3830

Patent

active

056864086

ABSTRACT:
A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 .mu.g/kg and less than about 500 .mu.g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.

REFERENCES:
patent: 4988675 (1991-01-01), Froesch
Guler, H.-P. et al. (1988) Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc. Natl. Acad. Sci. USA. 85:4889-4893.
Guler, H.-P. (1987) Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N. Engl. J. Med. 317:137-140.
Weinstein, R. et al. (1981) Hormonal requirements for growth of arterial smooth muscle cells in vitro: An Endocrine Approach to Atherosclesosis. Science 212:818-820.
Verspohl, E.J. et al. (1984) Dual regulation of glycogen metabolism by insulin and insulin-like growth factors in Human Hepatoma Cells (Hep-G2). J. Clin. Invest. 74:1436-1443.
Zenobi, P.D. et al. (1992) Insulin-like growth factor I improves glucose and lipid metabolism in type 2 diabetes mellitus. J. Clin. Invest. 90:2234-41.
Smith, P.J. et al. (1988). Insulin-like growth factor-I is an essential regulator of the differentiation of 3T3-Li adipocytes. J. Biol. Chem. 263:9402-9408.
Wilton, P. et al. (1991). Pharmacokinetic profile of recombinant human insulin-like growth factor I given subcutanceousley in normal subjects.
Takano, R. et al. (1991). Repeated sc administration of recombinant human insulin-like growth factor I (IGF-I) to human subjects for 7 days. Growth Reg. 1:23-28.
Laron, Z. et al. (1991). Biochemical and hormonal changes induced by one week of administration of rIGF-1 to patients with laron type dwarfism. Chin. Endocrinol. 35, 145-150.
Schoenle, E.J., et al., "Recombinant human insulin-like growth factor I (rhIGFI) . . . ", Diabetologia, pp. 675-679, 1991.
Usala, Anton-Lewis, et al., "Brief Rpt.: Treatment of Insulin-Resistant Diabetic . . . "; NEJM, vol. 327, No. 12, pp. 853-857, 1992.
Zenobi, Peter, et al., "Effects of IGF-I on Glucose Tolerance . . . "; J. Clin. Invest., vol. 89, pp. 1908-1913, Jun. 1992.
Schalch, Don S., et al., "Short-term metabolic effects of rhIGF-I . . . "; Modern Concepts of IGF, pp. 708-713, 1991.
Elahi, D., et al., "Hemodynamic and Metabolic Responses to Human IGFI . . . "; Modern Concepts of IGF, pp. 219-224, 1991.
Quin, John et al., "Acute Response to IGF-I in a Patient . . . ", Correspondence Section; NEJM, vol. 323, No. 20, pp. 1425-1426, 1990.

Affiliated with

Also associated with

Rating

Method for modifying, diagnosing, and screening for IGF-I sensit does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for modifying, diagnosing, and screening for IGF-I sensit, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for modifying, diagnosing, and screening for IGF-I sensit will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1229077